000			05671cam a2200433Ii 4500
001			95220
003			ES-MaUEC
005			20230102112652.0
006			m o d
007			cr cnu|||unuuu
008			170116s2017 sz o 001 0 eng d
020			_a3319453459 _q(electronic bk.)
020			_a9783319453453 _q(electronic bk.)
020			_z3319453440
020			_z9783319453446 _q(print)
035			_a(OCoLC)968705998 _z(OCoLC)968906356 _z(OCoLC)974651477 _z(OCoLC)981817093 _z(OCoLC)1005818766 _z(OCoLC)1011993163
040			_aN$T _cN$T _dIDEBK _dEBLCP _dGW5XE _dN$T _dOCLCF _dUAB _dNJR _dYDX _dOCLCO _dUPM _dOCLCO _dIOG _dOCLCO _dMERER _dESU _dZ5A _dOCLCO _dOCLCQ _dOCLCO _dJBG _dIAD _dOCLCO _dICW _dOCLCO _dICN _dOCLCQ _dOCLCO _dOTZ _dOCLCQ _dVT2 _dOCLCA _dOCLCO _dOCLCQ _dU3W _dOCLCO _dOCLCQ _dOCLCO _dES-MaUEC _bspa
050		4	_aRC388.5 _b2017 EB
245	0	0	_aNeuroprotective therapy for stroke and ischemic disease _cPaul A. Lapchak, John H. Zhang, editors.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aSpringer series in translational stroke research _x2363-958X
505	0		_aPreface; Contents; Contributors; Part I: Stroke Neuroprotection: The History and Learning Experience; Chapter 1: Reflections on€Neuroprotection Research and€the€Path Toward Clinical Success; 1 Introduction: A€Brief Chronological History of€Stroke; 1.1 Of Neurons and€Time; 1.1.1 Extrapolated Stroke and€Cerebrovascular Disease Incidence; 1.1.2 Time-brain matters!; 2 Limited Benefit Treatment Options for€Acute Ischemic Stroke Victims: Successes!; 2.1 Thrombolysis: Thrombolytic Therapy; 2.2 Endovascular Procedures and€Thrombolysis; 2.2.1 ESCAPE [32]: Table 1.3; 2.2.2 EXTEND-IA [33]: Table 1.4.
505	8		_a2.2.3 MR CLEAN [31]: Table 1.52.2.4 REVASCAT [34]: Table 1.6; 2.2.5 SWIFT-PRIME [35]: Table 1.7; 2.2.6 Endovascular Procedure Benefit; 2.3 Embolectomy Concerns; 2.3.1 Patient Population Selection for€Embolectomy and€Thrombolysis; 2.3.2 Limitations of€the€Trials; Patient Selection Bias; Saving Penumbra; Time to€Treatment; Coadministration of€Thrombolytics; 2.3.3 Future of€Embolectomy; Endovascular Procedure Summary; 3 Neuroprotection; 3.1 Evolving Opportunities; 3.2 The RIGORs of€Drug Development: Guideline Adherence; 3.3 Meta-analysis of€Translational Studies; 4 Comorbidities and€Models.
505	8		_a2.4 Providing Potential Explanations for€Discrepancies Between€Preclinical and€Clinical Trial Results2.5 Informing Clinical Trial Design; 3 Limitations of€Systematic Review and€Meta-analysis; 4 Future of€Preclinical Systematic Review and€Meta-analysis; 5 Conclusions; 6 Resources; References; Chapter 3: Neuroprotection Is Technology, Not Science; 1 Introduction; 2 Part 1: Physics and€Biology; 2.1 A Tale of€Two Cultures; 2.2 What Is Measured?; 2.3 The Mathematizing of€Biology; 3 Part 2: A€Theory of€Acute Cell Injury; 3.1 Introduction to€the€Theory; 3.2 Qualitative Description of€the€Theory.
505	8		_a3.3 The Autonomous Theory3.4 Solutions of€the€Autonomous Theory; 3.5 Monostable Outcome; 3.6 Bistable Outcome; 3.7 Pre-treatment Therapies; 3.8 Closed Trajectories and€the€Autonomous Theory; 4 Technological Applications; 4.1 Approaches to€Therapy; 4.2 Ascertaining Injury Intensity; 4.3 Protective Therapeutics; 4.4 The Non-autonomous Dynamical Theory of€Acute Cell Injury; 4.5 Sequential Injuries; 4.6 Solutions of€the€Multiple Injury Model; 4.6.1 Preconditioning; 4.6.2 Post-injury Drug Treatment; 4.7 Spatial Applications; 4.8 A Possible Neuroprotective Technology.
505	8		_a4.1 Hypertension Models4.2 Diabetic Models; 4.2.1 Coadministration of€Drugs in€Stroke Models; 5 Drug Development Considerations; 6 Conclusion; References; Chapter 2: Systematic Review and€Meta-analysis: Important Tools in€Understanding Drug Development for€Stroke; 1 Introduction; 2 Evidence-Based Approaches to€Understanding Translational Stroke Research; 2.1 Assessing the€Quality and€Range of€Available Evidence; 2.1.1 Quality of€Evidence; 2.1.2 Range of€Evidence; 2.2 Assessing for€Publication Bias; 2.3 Impacts of€Systematic Reviews.
520	3		_aThis book is a critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in both academia and industry; it serves to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently, stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. Divided into five sections, the proposed volume explores historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the most recent bench-side research.
650		7	_aEnfermedades cerebrovasculares _xPrevention. _2embne _0(OCoLC)fst00851388 _0 _9150775
700	1		_aLapchak, Paul A., _eeditor literario
700	1		_aZhang, J. H. _q(John H.), _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-45345-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95220 _d95220 _x1